Table 2.
Clinicopathologic Profile of TNBC Patients with miR-223 Underexpression and Overexpression
| Parameter | miR-223 Underexpressed | miR-223 Overexpressed | p-value |
|---|---|---|---|
| (n=20) | (n=33) | ||
| EGFR | |||
| Positive | 7 | 23 | 0.013a |
| Negative | 13 | 10 | |
| CK5/6 | |||
| Positive | 10 | 20 | |
| Negative | 10 | 13 | 0.57 |
| p53 Mutant | |||
| Positive | 7 | 15 | |
| Negative | 13 | 18 | 0.454 |
| Stage | |||
| Early | 3 | 4 | |
| Locally- advanced | 16 | 22 | |
| Metastatic | 1 | 7 | 0.209 |
| Tumor size | |||
| <5 cm | 4 | 9 | |
| ≥5 cm | 16 | 24 | 0.555 |
| Nodal status | |||
| Positive | 12 | 24 | |
| Negative | 8 | 9 | 0.336 |
| Distant metastasis | |||
| Present | 1 | 7 | |
| Absent | 19 | 26 | 0.113 |
| Age | |||
| <50 y.o | 6 | 17 | |
| ≥50 y.o | 14 | 16 | 0.126 |
| BMI | |||
| <25 | 11 | 23 | |
| ≥25 | 9 | 10 | 0.279 |
| Chemotherapy regimen | |||
| Platinum | 9 | 14 | |
| Non-platinum | 11 | 17 | |
| Missing | 0 | 2 | 0.559 |
Note: aStatistically significant.
Abbreviations: CK5/6, cytokeratin 5/6; BMI, body mass index.